ArticleThe journal of sexual medicine2019
Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer.
Article in The journal of sexual medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Quality of life and testosterone recovery after androgen deprivation therapy in high-risk prostate cancer patients: long-term data from a phase III trial.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Trial
- Association of PSA kinetics after testosterone recovery with subsequent recurrence: secondary analysis of a phase III randomized controlled trial.World journal of urology · 2023Trial
- Association between dose to specific pelvic substructures and urinary and sexual dysfunction following Single-Dose ablative radiotherapy for prostate Cancer: A post hoc analysis from the ABRUPT trial.Clinical and translational radiation oncology · 2026Article
- Impact of Testosterone Recovery on Oncologic Outcomes in High-Risk, Localized Prostate Cancer.The Prostate · 2025Article
- Testosterone therapy in patients with locoregional prostate cancer treated with prior androgen deprivation therapy and radiation: a retrospective single center review.Translational andrology and urology · 2025Article
- Article
- Study of the predictive value of testosterone in androgen deprivation therapy for metastatic hormone-sensitive prostate cancer-the dual clinical research center for western and eastern China.Frontiers in endocrinology · 2025Article
- Patients' Preferences for Attributes of Oral vs Injectable Androgen Deprivation Therapy in Prostate Cancer: A Discrete Choice Experiment.Patient preference and adherence · 2025Article
- The landscape of androgen deprivation therapies for the treatment of advanced prostate cancer.Future oncology (London, England) · 2024Review
- Testosterone recovery post discontinuation of androgen deprivation for the treatment of advanced prostate cancer.Future oncology (London, England) · 2024Article
- Patient Preferences for Attributes of Androgen Deprivation Therapies in Prostate Cancer: A Discrete Choice Experiment with Latent Class Analysis.Advances in therapy · 2024Article
- Longer time to testosterone recovery impacts favorably on outcomes for prostate cancer following androgen deprivation and radiotherapy.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2024Article
- Mental health outcomes in a population-based cohort of patients with prostate cancer.Journal of the National Cancer Institute · 2024Article
- Implications of Delayed Testosterone Recovery in Patients with Prostate Cancer.European urology open science · 2024Article
- Impact of neoadjuvant relugolix on patient-reported sexual function and bother.Frontiers in oncology · 2024Article
- Article
- Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer.Frontiers in oncology · 2023Article
- Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer.Clinical pharmacology and therapeutics · 2023Article
- Persistent Testosterone Suppression After Cessation of Androgen Deprivation Therapy for Prostate Cancer.Cureus · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionAndrogen deprivation therapy (ADT) is frequently used in the treatment of prostate cancer worldwide. Variable testosterone (T) recovery profiles after ADT cessation have been cited.
aimTo evaluate T recovery after cessation of ADT.
methodsWe reviewed our institutional prospectively maintained database of patients with prostate cancer who received ADT. Serum early morning total T (TT) levels, collected at baseline and periodically after ADT cessation, were analyzed. Patient age, baseline T level, duration of ADT, and presence of diabetes and sleep apnea were selected as potential predictors of T recovery. 3 metrics of T recovery after 24 months of ADT cessation were analyzed: return to non-castrate level (TT > 50 ng/dL), return to normal (T > 300 ng/dL), and return back to baseline level (BTB). Multivariable time-to-event analysis (Cox proportional hazards), χ
main outcome measuresTime and chance of T recovery to non-castrate level (TT > 50 ng/dL), return to normal (T > 300 ng/dL), and return BTB.
results307 men with a mean age of 65 ± 8 years were included. Mean duration of ADT was 17 ± 25 months, and median follow-up was 31 ± 35 months. Mean TT values were 379 ng/dL at baseline and 321 ng/dL at >24 months. At 24 months after cessation of ADT, 8% of men remained at castrate level, 76% returned to TT >300 ng/dL, and 51% had returned BTB. Lower baseline T levels (TT < 400 ng/dL) and ADT duration >6 months were associated with a lower likelihood of recovery to normal TT at 24 months. Age >65 years and receiving ADT for >6 months were significantly associated with a slower T recovery. CLINICAL IMPLICATIONS: T recovery after ADT is not certain and may take longer than expected. Considering the range of side effects of low T, we believe that these findings must be discussed with patients before initiating such therapies. STRENGTHS & LIMITATIONS: Our strengths consisted of a relatively large database, long follow-up, and clinically meaningful endpoints. Limitations included the retrospective design of the study.
conclusionT recovery rates after ADT cessation vary according to patient age, ADT duration, and baseline T levels. Approximately one-quarter of patients failed to normalize their TT level, and one-tenth of men remained at castrate levels 24 months after ADT cessation. Nascimento B, Miranda EP, Jenkins LC, et al. Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer. J Sex Med 2019;16:872-879.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.